SW
VERV

SVB Wealth’s Verve Therapeutics VERV Stock Holding History

SVB Wealth’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,170
Closed -$162K – 823
2024
Q1 		$162K Sell
12,170
-17
-0.1% -$225 ﹤0.01% 787
2023
Q4 		$170K Buy
+12,187
New +$151K ﹤0.01% 797
2022
Q4 		– Sell
-6,025
Closed -$207K – 1100
2022
Q3 		$207K Buy
+6,025
New +$192K ﹤0.01% 841

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

SVB Wealth's VERV Position: Q2 2024 in Review

SVB Wealth sold out of Verve Therapeutics (VERV) in Q2 2024, closing a stake of 12,170 shares — an estimated $162K sold.

SVB Wealth first reported a position in VERV in Q3 2022 and held it in 3 quarters. The position peaked at $207K in Q3 2022. 166 funds tracked by Wall St. Rank hold VERV as of Q2 2024.

  • SVB Wealth reported no remaining Verve Therapeutics position as of Q2 2024 after selling out during the quarter.
  • SVB Wealth sold 12,170 Verve Therapeutics shares in Q2 2024, an estimated $162K.
  • SVB Wealth first reported a position in Verve Therapeutics in Q3 2022 and held it in 3 quarters.
  • SVB Wealth's Verve Therapeutics position peaked at $207K in Q3 2022.
  • 166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2024.

Based on SVB Wealth's 13F filing for Q2 2024, filed 6 Aug 2024.